DMIC
AQST icon

Dixon Mitchell Investment Counsel’s Aquestive Therapeutics AQST Stock Holding History

Dixon Mitchell Investment Counsel’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,000
Closed -$10.4K – 96
2024
Q2 		$10.4K Hold
4,000
– – ﹤0.01% 108
2024
Q1 		$17K Buy
+4,000
New +$13.3K ﹤0.01% 118

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Dixon Mitchell Investment Counsel's AQST Position: Q3 2024 in Review

Dixon Mitchell Investment Counsel sold out of Aquestive Therapeutics (AQST) in Q3 2024, closing a stake of 4,000 shares — an estimated $10.4K sold.

Dixon Mitchell Investment Counsel first reported a position in AQST in Q1 2024 and held it in 2 quarters. The position peaked at $17K in Q1 2024. 117 funds tracked by Wall St. Rank hold AQST as of Q3 2024.

  • Dixon Mitchell Investment Counsel reported no remaining Aquestive Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Dixon Mitchell Investment Counsel sold 4,000 Aquestive Therapeutics shares in Q3 2024, an estimated $10.4K.
  • Dixon Mitchell Investment Counsel first reported a position in Aquestive Therapeutics in Q1 2024 and held it in 2 quarters.
  • Dixon Mitchell Investment Counsel's Aquestive Therapeutics position peaked at $17K in Q1 2024.
  • 117 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2024.

Based on Dixon Mitchell Investment Counsel's 13F filing for Q3 2024, filed 17 Oct 2024.